Purdue Looks To Patent Portfolio, FDA Guidance To Delay OxyContin Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Federal Circuit finds four OxyContin patents invalid, but authorized generics will continue to be only ones available for the near future.